Anlon Healthcare Limited: Monitoring Agency Report for the quarter and Nine Months ended December 31, 2025
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Anlon Healthcare has submitted the Monitoring Agency Report from CRISIL Ratings covering how it has used the money raised from its August 2025 IPO. The company raised Rs 12,103 lakh as gross proceeds, with net proceeds of Rs 10,589.95 lakh after issue expenses. As of December 31, 2025, Rs 9,579.04 lakh (about 79%) of the total has been deployed. The term loan repayment (Rs 500 lakh) and working capital funding (Rs 4,315 lakh) have been fully used. Capital expenditure for the proposed manufacturing expansion has used only Rs 634.99 lakh out of the planned Rs 3,071.95 lakh, with Rs 2,436.96 lakh still unutilized. General corporate purposes have used Rs 1,378.60 lakh of the Rs 2,703 lakh allocated. The report notes that while the company has received the Consent to Establishment (CTE) approval, other regulatory approvals for the expansion are still pending, and vendor arrangements have been modified from the original prospectus, though this flexibility was disclosed in the IPO document.
For shareholders, this is a routine compliance update showing IPO funds are broadly being used as promised, with no major deviations flagged. The slow deployment of the expansion capex (only ~21% used so far) and pending regulatory approvals could delay the planned capacity addition, which is a key growth driver highlighted in the IPO. No immediate negative signal for the stock, but investors should watch for further updates on the expansion timeline and approval status.